WO2015086738A3 - Hiv vaccine - Google Patents

Hiv vaccine Download PDF

Info

Publication number
WO2015086738A3
WO2015086738A3 PCT/EP2014/077358 EP2014077358W WO2015086738A3 WO 2015086738 A3 WO2015086738 A3 WO 2015086738A3 EP 2014077358 W EP2014077358 W EP 2014077358W WO 2015086738 A3 WO2015086738 A3 WO 2015086738A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv vaccine
hiv
relates
present
novel compositions
Prior art date
Application number
PCT/EP2014/077358
Other languages
French (fr)
Other versions
WO2015086738A2 (en
Inventor
Lars H. HØIE
Anker LUNDEMOSE
Mats ÖKVIST
Arnt Ove HOVDEN
Maja Sommerfelt GRØNVOLD
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Publication of WO2015086738A2 publication Critical patent/WO2015086738A2/en
Publication of WO2015086738A3 publication Critical patent/WO2015086738A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus

Abstract

The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel compositions of HIV-specific vaccine peptides.
PCT/EP2014/077358 2013-12-11 2014-12-11 Hiv vaccine WO2015086738A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13196620 2013-12-11
EP13196620.2 2013-12-11

Publications (2)

Publication Number Publication Date
WO2015086738A2 WO2015086738A2 (en) 2015-06-18
WO2015086738A3 true WO2015086738A3 (en) 2015-08-06

Family

ID=49725070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/077358 WO2015086738A2 (en) 2013-12-11 2014-12-11 Hiv vaccine

Country Status (1)

Country Link
WO (1) WO2015086738A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20155193A1 (en) 2015-11-03 2017-05-03 Italfarmaco Spa Physically and chemically stable oral Givinostat suspensions
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
CN106563124A (en) * 2016-10-19 2017-04-19 广西大学 Application of lipoic acid as vaccine adjuvant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052040A1 (en) * 1999-03-04 2000-09-08 Bionor Immuno As Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
WO2013182660A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
WO2015007337A1 (en) * 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052040A1 (en) * 1999-03-04 2000-09-08 Bionor Immuno As Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
WO2013182660A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
WO2015007337A1 (en) * 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Non-patent literature cited during the examination procedure submitted on 14.10.2005; Report - Clinical data phase II", INTERNET CITATION, 14 October 2005 (2005-10-14), pages 1 - 10, XP002717712, Retrieved from the Internet <URL:https://register.epo.org/application?number=EP00911492&lng=en&tab=doclist> [retrieved on 20131210] *
ANKER LUNDEMOSE: "Exploring the Path Towards a Functional Cure for HIV", 27 November 2013 (2013-11-27), XP055134825, Retrieved from the Internet <URL:http://www.bionorpharma.com/filestore/BionorNov2013.pdf> [retrieved on 20140814] *
RICHARD B POLLARD ET AL: "Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial", THE LANCET INFECTIOUS DISEASES, vol. 14, no. 4, 1 April 2014 (2014-04-01), pages 291 - 300, XP055134453, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(13)70343-8 *

Also Published As

Publication number Publication date
WO2015086738A2 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
EP3967323A3 (en) Hiv vaccine
PH12015501156A1 (en) Pharmaceutical compositions
PH12015502539B1 (en) Cenicriviroc compositions and methods of making and using the same
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201992133A1 (en) PIPERIDINO-PYRIMIDINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS
MX358099B (en) Human immunodeficiency virus neutralizing antibodies adn methods of use thereof.
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX2017003928A (en) Long acting pharmaceutical compositions.
PH12016500465B1 (en) Deoxynojirimycin derivatives and methods of their using
WO2013106689A8 (en) Hcv ns3 protease inhibitors
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
MX343505B (en) Methods and compositions for inhibiting hiv transmission.
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
WO2016011324A3 (en) 5&#39;-triphosphate oligoribonucleotides
WO2015086738A3 (en) Hiv vaccine
WO2016100615A3 (en) Methods and composition for neutralization of influenza
PH12015502564B1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
WO2014210082A3 (en) Camptothecin derivatives as anti-hiv agents and methods of identifying agents that disrupt vif self-association
WO2014025749A3 (en) Small molecule inhibitors of viral protein interactions with human t-rna
WO2015051268A3 (en) Hiv protease inhibitors against picornavirus infection
WO2014124092A3 (en) Lamivudine crystalline salts
WO2016112339A8 (en) Stable formulations for the oral administration of amphotericin b and related methods
WO2011109104A3 (en) Molecular clone of hiv-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14812211

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16.09.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14812211

Country of ref document: EP

Kind code of ref document: A2